PT118087A - Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxol - Google Patents
Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxolInfo
- Publication number
- PT118087A PT118087A PT118087A PT11808722A PT118087A PT 118087 A PT118087 A PT 118087A PT 118087 A PT118087 A PT 118087A PT 11808722 A PT11808722 A PT 11808722A PT 118087 A PT118087 A PT 118087A
- Authority
- PT
- Portugal
- Prior art keywords
- mcak
- taxol
- ttl
- detyrosination
- tubulin
- Prior art date
Links
- 101710134369 Kinesin-like protein KIF2C Proteins 0.000 title abstract 5
- 102100023424 Kinesin-like protein KIF2C Human genes 0.000 title abstract 5
- 229930012538 Paclitaxel Natural products 0.000 title abstract 5
- 229960001592 paclitaxel Drugs 0.000 title abstract 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 206010070834 Sensitisation Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 230000008313 sensitization Effects 0.000 title abstract 3
- 230000004044 response Effects 0.000 title 1
- 102000029749 Microtubule Human genes 0.000 abstract 4
- 108091022875 Microtubule Proteins 0.000 abstract 4
- 102000004243 Tubulin Human genes 0.000 abstract 4
- 108090000704 Tubulin Proteins 0.000 abstract 4
- 210000004688 microtubule Anatomy 0.000 abstract 4
- 239000003381 stabilizer Substances 0.000 abstract 4
- 239000003795 chemical substances by application Substances 0.000 abstract 3
- 108091033409 CRISPR Proteins 0.000 abstract 2
- 238000010354 CRISPR gene editing Methods 0.000 abstract 2
- 108091027967 Small hairpin RNA Proteins 0.000 abstract 2
- 108091027544 Subgenomic mRNA Proteins 0.000 abstract 2
- 229940123237 Taxane Drugs 0.000 abstract 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 abstract 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 abstract 1
- 239000003963 antioxidant agent Substances 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 239000006172 buffering agent Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 239000012660 pharmacological inhibitor Substances 0.000 abstract 1
- 229920002477 rna polymer Polymers 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
- 229930002368 sesterterpene Natural products 0.000 abstract 1
- 150000002653 sesterterpene derivatives Chemical class 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A PRESENTE INVENÇÃO REVELA QUE O AUMENTO DA DESTIROSINAÇÃO DA Α- TUBULINA ATRAVÉS RESULTA EM MAIOR SENSIBILIDADE AO TAXOL. COMO TAL, A PRESENTE INVENÇÃO REFERE-SE A AGENTES DE AUMENTO DA DESTIROSINAÇÃO DA Α-TUBULINA PARA USO NO TRATAMENTO DO CANCRO ATRAVÉS DA SENSIBILIZAÇÃO AO TAXOL, TAXANOS E OUTROS AGENTES ESTABILIZADORES DE MICROTÚBULOS (MT). OS DITOS AGENTES DE AUMENTO DA DESTIROSINAÇÃO DA Α-TUBULINA COMPREENDEM PEQUENOS ÁCIDOS RIBONUCLEICOS DE INTERFERÊNCIA (SIRNA)EM ¿GANCHO DE CABELO¿ PARA A TTL (SHRNA), RNAS DE GUIA ÚNICA/REPETIÇÕES PALINDRÓMICAS CURTAS REGULARMENTE INTERESPAÇADAS AGRUPADAS (SGRNA/CRISPR) PARA A TTL, INIBIDORES FARMACOLÓGICOS DA TTL (UM EXEMPLO CONSISTINDO DE SESTERTERPENOS), SIRNA PARA A MCAK, SHRNA PARA MCAK, SGRNA/CRISPR PARA MCAK, INIBIDORES FARMACOLÓGICOS MCAK (EXEMPLOS CONSISTEM EM 2021-4 C4, 2030-1 B4 E 2042 H9) E SUAS COMBINAÇÕES. O USO DA PRESENTE INVENÇÃO COMPREENDE AINDA COMBINAÇÕES COM TAXOL, TAXANOS E OUTROS AGENTES ESTABILIZADORES DE MT. A PRESENTE INVENÇÃO TAMBÉM SE REFERE A UMA COMPOSIÇÃO FARMACÊUTICA PARA USO NO TRATAMENTO DO CANCRO ATRAVÉS DA SENSIBILIZAÇÃO A TAXOL, TAXANOS E OUTROS AGENTES ESTABILIZADORES DE MT CARACTERIZADA POR, COMPREENDER AGENTES DE AUMENTO DE DESTIROSINAÇÃO DA Α-TUBULINA CONFORME DESCRITO NAS REIVINDICAÇÕES 1-4 ASSIM COMO OUTROS COMPOSTOS SELECIONADOS DO GRUPO CONSTITUÍDO POR UM EXCIPIENTE, UM DILUENTE, UM AGENTE ESTABILIZANTE, UM TRANSPORTADOR, UM SURFACTANTE, UM ANTIOXIDANTE UM AGENTE TAMPONANTE, E SUAS COMBINAÇÕES.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT118087A PT118087A (pt) | 2022-07-06 | 2022-07-06 | Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxol |
| PCT/PT2023/050019 WO2024010480A1 (en) | 2022-07-06 | 2023-07-06 | Suppressors of ttl and mcak for use in the treatment of cancer through sensitization to taxol response |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PT118087A PT118087A (pt) | 2022-07-06 | 2022-07-06 | Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxol |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT118087A true PT118087A (pt) | 2024-01-08 |
Family
ID=87517196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT118087A PT118087A (pt) | 2022-07-06 | 2022-07-06 | Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxol |
Country Status (2)
| Country | Link |
|---|---|
| PT (1) | PT118087A (pt) |
| WO (1) | WO2024010480A1 (pt) |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7294640B2 (en) * | 2004-02-06 | 2007-11-13 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| CN101812127B (zh) * | 2009-02-19 | 2013-03-06 | 中国科学技术大学 | 微管结合蛋白及其编码基因与应用 |
| US20110313021A1 (en) * | 2010-06-19 | 2011-12-22 | Jack Zilfou | Method to rapidly identify critical p53 target genes that can be utilized for therapeutic intervention |
| DE18200782T1 (de) | 2012-04-02 | 2021-10-21 | Modernatx, Inc. | Modifizierte polynukleotide zur herstellung von proteinen im zusammenhang mit erkrankungen beim menschen |
-
2022
- 2022-07-06 PT PT118087A patent/PT118087A/pt unknown
-
2023
- 2023-07-06 WO PCT/PT2023/050019 patent/WO2024010480A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2024010480A1 (en) | 2024-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2021002326A1 (es) | Composiciones de arni contra el angiotensinógeno (agt) y métodos para su uso (divisional de solicitud n° 202002865) | |
| Xiao et al. | Retracted: lnc RNA MALAT 1 increases the stemness of gastric cancer cells via enhancing SOX 2 mRNA stability | |
| BR112022021136A2 (pt) | Composições de irna de fator b de complemento (cfb) e métodos de uso das mesmas | |
| Tang et al. | Extracellular calcium elicits feedforward regulation of the Toll-like receptor-triggered innate immune response | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| UY37952A (es) | Formulaciones de un inhibidor de la quinasa trk macrocíclica | |
| Wu et al. | Induction of microRNA-146a is involved in curcumin-mediated enhancement of temozolomide cytotoxicity against human glioblastoma | |
| BR112022002059A2 (pt) | Formas sólidas de um inibidor de hpk1 | |
| Xie et al. | The endoplasmic reticulum stress-autophagy pathway is involved in apelin-13-induced cardiomyocyte hypertrophy in vitro | |
| BR112016013148A2 (pt) | "composições de rnai de componente do complemento e métodos de utilização das mesmas | |
| BRPI0717970B8 (pt) | composto inibidor de 11betahsd1, composição farmacêutica, e, uso do composto | |
| CL2021001042A1 (es) | Nuevos compuestos antihelmínticos | |
| BR112023016645A2 (pt) | Composições de irna de ceto-hexoquinase (khk) e métodos de uso das mesmas | |
| BR112022017822A2 (pt) | Composições de irna de cetoexocinase (khk) e métodos de uso das mesmas | |
| Cho et al. | Essential oil of Pinus koraiensis inhibits cell proliferation and migration via inhibition of p21-activated kinase 1 pathway in HCT116 colorectal cancer cells | |
| BR112022024420A2 (pt) | Composições de irna de xantina desidrogenase (xdh) e métodos de uso das mesmas | |
| BR112023024942A2 (pt) | Uso de inibidores de atr em combinação com inibidores de parp para tratamento de câncer | |
| AR091155A1 (es) | Composicion farmaceutica acuosa que contiene un agente terapeutico biologico y guanidina o un derivado de guanidina y una inyeccion que incluye la composicion | |
| Chen et al. | The anti-inflammatory effects of asiatic acid in lipopolysaccharide-stimulated human corneal epithelial cells | |
| Gee et al. | A novel and selective p38 mitogen-activated protein kinase inhibitor attenuates LPS-induced neuroinflammation in BV2 microglia and a mouse model | |
| UY38153A (es) | Formulaciones acuosas estables de anticuerpos anti-tau | |
| PT118087A (pt) | Supressores de ttl e mcak para uso no tratamento do cancro através da sensibilização à resposta ao taxol | |
| MX2020006012A (es) | Composiciones de arni de la caja 1 del grupo de alta movilidad (hmgb1) y métodos de uso de las mismas. | |
| BR112023023578A2 (pt) | Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda | |
| BR112023018654A2 (pt) | Compostos antibacterianos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| BB1A | Laying open of patent application |
Effective date: 20231220 |